Jaffetilchin Investment Partners LLC buys 2,155 shares of CVS Health Co. (NYSE:CVS)

Jaffetilchin Investment Partners LLC raised its position in shares of CVS Health Co. (NYSE:CVS – Free Report) by 33.1% in the second quarter, Holdings Channel reports. The fund owned 8,657 shares of the pharmacy operator’s stock after buying an additional 2,155 shares during the quarter. Jaffetilchin Investment Partners LLC’s holdings in CVS Health were worth $511,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have added to or reduced their stakes in CVS. Norges Bank bought a new stake in CVS Health in the fourth quarter valued at $1,092,040,000. Capital International Investors boosted its holdings in CVS Health by 47.4% in the fourth quarter. Capital International Investors now owns 33,691,698 shares of the pharmacy operator’s stock valued at $2,660,298,000 after buying an additional 10,837,801 shares during the period. Pzena Investment Management LLC grew its position in shares of CVS Health by 573.8% in the first quarter. Pzena Investment Management LLC now owns 5,553,457 shares of the pharmacy operator’s stock worth $442,944,000 after buying an additional 4,729,207 shares during the last quarter. Capital World Investors increased its position in shares of CVS Health by 8.0% in the first quarter. Capital World Investors now owns 43,776,874 shares of the pharmacy operator’s stock worth $3,491,643,000 after buying an additional 3,232,172 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its stake in CVS Health by 306.6% in the fourth quarter. Clearbridge Investments LLC now owns 3,046,216 shares of the pharmacy operator’s stock valued at $240,529,000 after buying an additional 2,297,100 shares during the period. 80.66% of the shares are currently held by institutional investors.

CVS Health Price Performance

Shares of CVS Health opened at $57.24 on Friday. The stock has a market cap of $72.01 billion, a P/E ratio of 10.06, a price-to-earnings-growth ratio of 0.80 and a beta of 0.52. CVS Health Co. has a one year low of $52.77 and a one year high of $83.25. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.86, and a quick ratio of 0.66. The company’s 50-day SMA is $58.50, and its 200-day SMA is $64.52.

CVS Health (NYSE:CVS – Get Your Free Report ) last posted its earnings results on Wednesday, August 7th. The pharmacy operator reported $1.83 EPS for the quarter, topping the consensus estimate of $1.73 by $0.10. The company had revenue of $91.23 billion for the quarter, compared to the consensus estimate of $91.41 billion. CVS Health had a net margin of 1.98% and a return on equity of 12.72%. The company’s revenue for the quarter was up 2.6% year-over-year. In the same period last year, the firm earned $2.21 per share. Analysts estimate that CVS Health Co. will record 6.52 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Monday, July 22nd were paid a $0.665 dividend. The ex-dividend date of this dividend was Monday, July 22. This represents an annualized dividend of $2.66 and a dividend yield of 4.65%. CVS Health’s payout ratio is currently 46.75%.

The Wall Street analyst weighs in

CVS has been the subject of several recent analyst reports. TD Cowen cut CVS Health from a “buy” rating to a “hold” rating and cut their price target for the company from $99.00 to $59.00 in a report on Tuesday, May 7th . Deutsche Bank Aktiengesellschaft dropped their target price on shares of CVS Health from $64.00 to $63.00 and set a “hold” rating on the stock in a research note on Friday, August 9th. Cantor Fitzgerald reissued a “neutral” rating and issued a $62.00 target price on shares of CVS Health in a report on Monday, August 19th. Baird RW upgraded shares of CVS Health to a “hold” rating in a research report on Thursday, May 30th. Finally, Robert W. Baird initiated coverage on CVS Health in a research note on Thursday, May 30th. They issued a “neutral” rating and a $61.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Moderate Buy” and an average price target of $73.24, according to MarketBeat.com.

Check out our latest analysis of CVS Health

CVS Health Company Profile

(Free report)

CVS Health Corporation provides healthcare solutions in the United States. It operates through the Health Care Benefits, Health Services, and Pharmacy & Consumer Health segments. The Healthcare Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services.

Featured stories

Want to see what other hedge funds own CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for CVS Health Co. (NYSE:CVS – Free Report).

Get news and reviews for CVS Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CVS Health and related companies with MarketBeat.com’s FREE daily email newsletter.